Tipranavir (Aptivus)
Overview
- A Clinical Overview of Tipranavir (Aptivus) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health - Prescribing Information for Tipranavir (Aptivus) (PDF) (October 2007)
From Boehringer Ingelheim - Tipranavir: The First Nonpeptidic Protease Inhibitor (Winter 2003/2004)
To read PDF, click here
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
News
- New Pediatric Dosing for Aptivus, Patients 2-18 Years, New Oral Solution and Info on Coadministration With Midazolam (June 23, 2008)
From U.S. Food and Drug Administration - FDA Approval of Aptivus (Tipranavir) (June 23, 2005)
From U.S. Food and Drug Administration - U.S. FDA Approves New Anti-HIV Drug Aptivus for Use in Combination Therapy (June 23, 2005)
From Boehringer Ingelheim - Tipranavir (Aptivus): Approval Cautiously Recommended (June 20, 2005)
In AIDS Treatment News, from AIDS Treatment News - Tipranavir Patients May Experience Intracranial Hemorrhage, FDA Warns (June 30, 2006)
From U.S. Food and Drug Administration
Research
- Literature Citations for Tipranavir (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Tipranavir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - New Data on Tipranavir Highlight the Agent's Benefits (July 25, 2007)
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - A Research Update on Tipranavir (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - A Thorough Look at Tipranavir Based on Studies Assessing Its Efficacy, Resistance and Safety (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - Tipranavir/Ritonavir-Associated Hepatotoxicity Common, But Resolves Over Time (September 30, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Virologic Outcomes With Tipranavir + Ritonavir Prove to Be Durable Out to 96 Weeks in the RESIST Studies (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Whereas Other PIs Fail, Tipranavir Maintains High-Level Potency Against Key PI Resistance Mutations (September 28, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Ritonavir-Boosted Tipranavir More Effective Than Other Ritonavir-Boosted PIs in HIV-Infected Patients With PI Resistance (August 17, 2006)
In XVI International AIDS Conference - Use of Tipranavir for Patients With Little Prior PI Experience (August 15, 2006)
In XVI International AIDS Conference - Tipranavir Update at CROI 2006: RESIST Study Results, Drug Interactions and Therapeutic Drug Monitoring (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - Ritonavir-Boosted Tipranavir Increases ALT and AST Levels in HIV/Hepatitis-Coinfected Patients (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Tipranavir Heralds New Era for Treatment-Experienced Patients, Recent Studies Attest (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Ritonavir-Boosted Tipranavir Update at CROI 2005 (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Research Updates on Tipranavir, TMC-114 and TMC-125 (December 2004)
A review of the tipranavir RESIST studies, a note on potential tipranavir pricing, and a critical look at two developing rescue drugs.
In TAGline, from Treatment Action Group - Tipranavir Reduces Concentrations of Other Protease Inhibitors (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO - Tipranavir Pharmacokinetics May Confine Its Use to Limited Rescue Role (June 2004)
In TAGline, from Treatment Action Group - No Interactions Between Tipranavir/Ritonavir and Efavirenz, Tenofovir and AZT (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - The Inhibitory Quotient in Tipranavir/Ritonavir (July 14, 2003)
Therapeutic drug monitoring and phenotypic resistance testing are also found to be a valuable predictor of response.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Tipranavir/Ritonavir's Resistance Profile in Multiple-Protease-Inhibitor-Experienced Patients (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Tipranavir: Hare-Raising Comparison (April 2003)
A summary of study results from CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Tipranavir/Ritonavir Demonstrates Potent Efficacy in Multiple Protease Inhibitor-Experienced Patients: BI 1182.52 (February 14, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Correlation of Viral Load Reduction and Plasma Levels in Multiple Protease Inhibitor-Experienced Patients Taking Tipranavir/Ritonavir in a Phase IIB Trial: BI 1182.52 (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Baseline Phenotypic Susceptibility to Tipranavir/Ritonavir Is Retained in Isolates From Patients With Multiple Protease Inhibitor Experience (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - New Anti-HIV Therapies: Tipranavir (January 2003)
From Project Inform - Tipping the Scales at 500 mg -- Tipranavir! (December 2002)
In GMHC Treatment Issues, from Gay Men's Health Crisis - Tipranavir/Ritonavir: Derivation of Doses That Achieve Effective Plasma Concentrations Above the IC50 for Multiple PI-Resistant HIV-1 Viruses (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Resistance to Tipranavir is Uncommon in a Randomized Trial of Tipranavir/Ritonavir (TPV/RTV) in Multiple PI-Failure Patients (BI 1182.2) (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Safety and Efficacy of Tipranavir (TPV), a Novel Non-Peptidic Protease Inhibitor, Plus Ritonavir (RTV) in PI-Failure Patients (December 18, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Tipranavir: The First Non-Peptidic Protease Inhibitor (October 28, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Safety and Efficacy of Tipranavir, a Non-Peptidic Protease Inhibitor, in Multiple PI-Failure Patients (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Drug Interactions: Tipranavir (February 2002)
From Project Inform - Study of Tipranavir for First-Line Treatment Ends Early (June 9, 2006)
Newly released results from an industry-sponsored study make it doubtful that tipranavir will ever be used as first-line therapy.
From Boehringer Ingelheim
Clinical Management
Clinical Management
  |